Key Highlights

  • Shares are trading at $6.38 in pre-market activity, down 3.77% from Monday's close of $6.63.
  • Subsidiary NeuroThera Labs reported that 26 of a planned 60 children have been enrolled in its Phase 2 SCI-210 autism spectrum disorder trial.
  • The double-blind, placebo-controlled trial is being conducted at a medical center in Israel.
  • SCI-210 combines cannabidiol with the company's proprietary CannAmide formulation.
  • Market Capitalization stands at approximately $383.47 million, with Earnings Per Share of negative $161.98.

Shares Fall Despite an Update on Trial Progress

Shares of SciSparc (NASDAQ:SPRC) fell in pre-market trading even as its majority-owned subsidiary, NeuroThera Labs, reported continued progress in a closely watched pediatric clinical trial, a reaction that runs counter to the update's seemingly positive tone. SciSparc is a Tel Aviv-based clinical-stage specialty pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.

NeuroThera announced that 26 of a planned 60 children have now been enrolled in a Phase 2 trial assessing SCI-210, an experimental treatment for symptoms associated with autism spectrum disorder.

Trial Design and What the Update Actually Showed

The double-blind, randomized, placebo-controlled study, conducted at a medical center in Israel, is evaluating the treatment in children between five and 18 years old, each receiving therapy over a 20-week period. The experimental compound combines cannabidiol with a proprietary formulation the Subsidiary has developed, and the trial's primary endpoints include a parent-reported behavior questionnaire and a clinician-assessed global impression scale. The update disclosed enrollment progress only, with no efficacy or safety data released, which may explain why the news did not translate into a positive stock reaction.

Why the Stock May Be Falling Regardless

The available reference material does not point to a separate, more market-moving catalyst behind today's decline. The move appears more consistent with the stock's already high Volatility as a micro-cap clinical-stage name, where shares can react to broader risk sentiment or profile-driven trading independent of incremental trial updates.

Outlook: Data Readout Remains the Real Catalyst

With today's news limited to an enrollment update rather than trial results, the stock's next meaningful catalyst is likely to be actual efficacy and safety data from the ongoing trial rather than incremental enrollment milestones. Investors will be watching for full enrollment of the planned 60-patient cohort and eventual topline results.